Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Ferrari NV (RACE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Ferrari NV — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Ferrari NV trades at $376.2 (market cap $66.31B). The key difference: Ferrari NV is the larger of the two by market cap, and Ferrari NV pays a 1.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | RACE | |
|---|---|---|
Market Cap | $39.89B | $66.31B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $517.65 |
52-Week Low | $278.09 | $314.63 |
Enterprise Value | $38.15B | $67.52B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Ferrari (RACE) trades at $376.64, up 0.53% with bullish technical signals and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.73 exceeding expectations. Revenue grew to $7.15B in 2025, supported by a 22.19% net margin and 41.96% ROE. Recent news highlights include a new EV model launch and ongoing share buybacks, while technical indicators point to support near $372 and resistance at $377.
The outlook remains positive with a consensus price target of $467.50, implying 24% upside. Key risks include execution challenges with new electric vehicles and economic sensitivity. Analyst sentiment is strongly bullish (72% buy ratings), but investors should monitor competitive pressures and margin sustainability amid hybrid transition efforts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →
